190 related articles for article (PubMed ID: 17699797)
21. Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy.
Wang J; Seethala RR; Zhang Q; Gooding W; van Waes C; Hasegawa H; Ferris RL
J Natl Cancer Inst; 2008 Apr; 100(7):502-12. PubMed ID: 18364504
[TBL] [Abstract][Full Text] [Related]
22. SYK is a candidate kinase target for the treatment of advanced prostate cancer.
Ghotra VP; He S; van der Horst G; Nijhoff S; de Bont H; Lekkerkerker A; Janssen R; Jenster G; van Leenders GJ; Hoogland AM; Verhoef EI; Baranski Z; Xiong J; van de Water B; van der Pluijm G; Snaar-Jagalska BE; Danen EH
Cancer Res; 2015 Jan; 75(1):230-40. PubMed ID: 25388286
[TBL] [Abstract][Full Text] [Related]
23. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
Kunze E; Wendt M; Schlott T
Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
[TBL] [Abstract][Full Text] [Related]
24. [Study of the expression and function of Syk and VEGF-C in the development of non-small cell lung cancer].
Guo JZ; Sun QF; Cong B; Zhao YP; Peng CL; Zhao XG
Zhonghua Yi Xue Za Zhi; 2013 Dec; 93(47):3801-3. PubMed ID: 24548403
[TBL] [Abstract][Full Text] [Related]
25. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
26. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR.
Wang J; Zhang X; Thomas SM; Grandis JR; Wells A; Chen ZG; Ferris RL
Oncogene; 2005 Sep; 24(38):5897-904. PubMed ID: 16007209
[TBL] [Abstract][Full Text] [Related]
27. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival.
Dejmek J; Leandersson K; Manjer J; Bjartell A; Emdin SO; Vogel WF; Landberg G; Andersson T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):520-8. PubMed ID: 15701836
[TBL] [Abstract][Full Text] [Related]
28. Elevated expression of T-lymphoma invasion and metastasis inducing factor 1 in squamous-cell carcinoma of the head and neck and its clinical significance.
Wang S; Li S; Yang X; Yang S; Liu S; Liu B; Liu J
Eur J Cancer; 2014 Jan; 50(2):379-87. PubMed ID: 24189000
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of syk transfection on lung cancer cell invasion.
Peng CL; Zhang Y; Sun QF; Zhao YP; Hao YT; Zhao XG; Cong B
Asian Pac J Cancer Prev; 2013; 14(5):3001-3. PubMed ID: 23803069
[TBL] [Abstract][Full Text] [Related]
30. Progressive loss of Syk and abnormal proliferation in breast cancer cells.
Moroni M; Soldatenkov V; Zhang L; Zhang Y; Stoica G; Gehan E; Rashidi B; Singh B; Ozdemirli M; Mueller SC
Cancer Res; 2004 Oct; 64(20):7346-54. PubMed ID: 15492255
[TBL] [Abstract][Full Text] [Related]
31. Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.
Bailet O; Fenouille N; Abbe P; Robert G; Rocchi S; Gonthier N; Denoyelle C; Ticchioni M; Ortonne JP; Ballotti R; Deckert M; Tartare-Deckert S
Cancer Res; 2009 Apr; 69(7):2748-56. PubMed ID: 19293188
[TBL] [Abstract][Full Text] [Related]
32. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer.
Wang L; Duke L; Zhang PS; Arlinghaus RB; Symmans WF; Sahin A; Mendez R; Dai JL
Cancer Res; 2003 Aug; 63(15):4724-30. PubMed ID: 12907655
[TBL] [Abstract][Full Text] [Related]
33. Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells.
Zhang X; Shrikhande U; Alicie BM; Zhou Q; Geahlen RL
Mol Cancer Res; 2009 May; 7(5):634-44. PubMed ID: 19435818
[TBL] [Abstract][Full Text] [Related]
34. Migration inhibition of mammary epithelial cells by Syk is blocked in the presence of DDR1 receptors.
Neuhaus B; Bühren S; Böck B; Alves F; Vogel WF; Kiefer F
Cell Mol Life Sci; 2011 Nov; 68(22):3757-70. PubMed ID: 21499918
[TBL] [Abstract][Full Text] [Related]
35. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation.
Gschwind A; Prenzel N; Ullrich A
Cancer Res; 2002 Nov; 62(21):6329-36. PubMed ID: 12414665
[TBL] [Abstract][Full Text] [Related]
36. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
37. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells.
Coopman PJ; Do MT; Barth M; Bowden ET; Hayes AJ; Basyuk E; Blancato JK; Vezza PR; McLeskey SW; Mangeat PH; Mueller SC
Nature; 2000 Aug; 406(6797):742-7. PubMed ID: 10963601
[TBL] [Abstract][Full Text] [Related]
38. Mutations in the activation loop tyrosines of protein tyrosine kinase Syk abrogate intracellular signaling but not kinase activity.
Zhang J; Kimura T; Siraganian RP
J Immunol; 1998 Oct; 161(8):4366-74. PubMed ID: 9780214
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis.
Chakraborty G; Rangaswami H; Jain S; Kundu GC
J Biol Chem; 2006 Apr; 281(16):11322-31. PubMed ID: 16474166
[TBL] [Abstract][Full Text] [Related]
40. Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck.
Bock JM; Sinclair LL; Bedford NS; Jackson RE; Lee JH; Trask DK
Arch Otolaryngol Head Neck Surg; 2008 Apr; 134(4):355-62. PubMed ID: 18427000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
